No definition available.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
|
1. Apply sex-specific ruleonly males |
- |
2. Check conditions
|
- |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
3 out of 7 registries used, show all original rules. |
- |
4. Check minimum number of eventsNone |
- |
5. Include endpointsNone |
- |
6. Filter based on genotype QC (FinnGen only)None |
- |
Control definitions (FinnGen only)
- Control exclude
- C3_CANCER, C3_CANCER_WIDE
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF9
- Parent code in ICD-10
- D07
- Name in latin
- Carcinoma in situ oculi
Similar endpoints
↥List of similar endpoints to
Carcinoma in situ of prostate
based on the number of shared cases.
Similar with more cases:
- Carcinoma in situ of prostate
- Any operation in hilmo
- Any event in hilmo or specialist outpatient
- Any prescribed medicine buy
Similar with less cases:
Case counts by codes
↥FinnGen case counts by registry codes:
No upset plot: script not run.
No upset table: script not run.
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 42 | - | 42 |
| Only index persons | 20 | - | 20 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.00 | - | 0.00 |
| Only index persons | 0.00 | - | 0.00 |
| Median age at first event (years) | |||
| Whole population | - | - | 74.45 |
| Only index persons | - | - | 69.37 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 190 | - | 190 |
| Unadjusted period prevalence (%) | 0.08 | - | 0.08 |
| Median age at first event (years) | 68.07 | - | 68.07 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
No data
-FinnGen-
Cumulative Incidence Function
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 180
- Matched controls
- 1800
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
8148/2-C61.9
ICD-O-3
Glandular intraepithelial neoplasia, high grade of prostate gland
+∞
200.5
153
*
KE1AT
NOMESCO Finland
Biopsy of prostata with ultrasoudnguidance
59.3
76.5
89
29
R74.8
ICD-10 Finland
Abnormal levels of other serum enzymes
31.0
58.4
80
45
C61
ICD-10 Finland
Malignant neoplasm of prostate
738.0
56.9
53
*
R86.0
ICD-10 Finland
Abnormal findings in specimens from male genital organs, abnormal level of enzymes
55.5
44.6
52
13
8140/3-C61.9
ICD-O-3
Adenocarcinoma, NOS, of prostate gland
+∞
40.1
37
*
XKD00
NOMESCO Finland
Uroflowmetry
7.8
35.1
111
308
N40
ICD-10 Finland
Hyperplasia of prostate
6.4
28.4
136
586
KC1EE
NOMESCO Finland
Ultrasound measurement of residual urine
6.6
28.3
93
250
TKE00
NOMESCO Finland
Needle biopsy of prostate
18.7
25.8
40
27
8140/2-C61.9
ICD-O-3
Adenocarcinoma in situ, NOS, of prostate gland
+∞
24.5
23
*
KEC01
NOMESCO Finland
Percutaneous endoscopic radical prostatectomy
+∞
23.4
22
*
KEB00
NOMESCO Finland
Biopsy of prostate
96.2
23.3
25
*
KE1DG
NOMESCO Finland
Very extensive MRI of prostate
62.2
19.4
22
*
KE1BE
NOMESCO Finland
Rectal ultrasound examinaiton of prostata
4.9
16.7
63
178
ZXC96
NOMESCO Finland
Robot assisted procedure
+∞
15.9
15
*
XJH00
NOMESCO Finland
Transanal ultrasonography
6.2
14.2
40
79
KDE20
NOMESCO Finland
Removal of foreign body from urethra
34.8
12.8
16
5
KC1GB
NOMESCO Finland
Cystography with X-ray
+∞
10.5
10
*
8090/3-C44.9
ICD-O-3
Basal cell carcinoma, NOS, of skin, NOS
+∞
10.5
10
*
Z03.1
ICD-10 Finland
Observation for suspected malignant neoplasm
12.3
10.3
18
16
WF002
NOMESCO Finland
Radical radiotherapy
105.3
9.5
10
*
UKC02
NOMESCO Finland
Cystoscopy
3.2
8.8
54
215
C44.31
ICD-10 Finland
Basocellular carcinoma of the skin on another or unspecified part of the face
94.2
8.5
9
*
130
Kela drug reimbursment
Malignant tumour
+∞
8.4
8
*
KE3AT
NOMESCO Finland
Transrectal gold marker implantation in prostate under ultrasound guidance
+∞
7.3
7
*
YL1BD
NOMESCO Finland
Extensive CT examination of pelvis for dose design of radiotherapy
+∞
7.3
7
*
ZX070
NOMESCO Finland
Intensity modified radiotherapy
+∞
7.3
7
*
JN2CG
NOMESCO Finland
Extensive MRI examination of lower part of abdoment with high intensity magnet
31.4
7.2
9
*
R39.1
ICD-10 Finland
Other difficulties with micturition
6.8
7.1
17
27
308
Kela drug reimbursment
Alprostadil, sildenafil and combination product containing aviptadil and phentolamine
41.6
6.8
8
*
WZC20
NOMESCO Finland
Multidisciplinary treatment meeting
12.9
6.7
11
9
WD125
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
+∞
6.3
6
*
C67.8
ICD-10 Finland
Malignant neoplasm: Overlapping lesion of bladder
+∞
6.3
6
*
WF049
NOMESCO Finland
Radiotherapy of metastasis
+∞
6.3
6
*
R33
ICD-10 Finland
Retention of urine
3.2
6.0
33
119
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
149
737
5.73
24.89
6.3
2.8
0.9
0.7
ug/l
3.30
136
516
121
569
4.10
20.05
4.9
3.0
—
—
—
0
0
101
425
3.94
19.59
4.5
2.9
0.2
0.4
e6/l
1.31
91
310
111
557
3.39
15.34
4.7
3.4
—
—
—
0
0
165
1079
5.02
14.80
8.2
3.9
15.5
24.0
%
26.89
141
516
64
259
3.22
12.17
4.4
2.9
0.3
0.7
e6/l
1.09
50
148
123
718
3.02
12.04
6.0
4.5
0.0
0.0
estimate
0.00
44
112
124
731
3.00
11.85
4.5
3.3
0.0
0.0
estimate
0.00
44
101
180
1340
7.52
11.78
10.4
4.0
6.2
2.0
ug/l
25.89
173
1202
122
716
2.97
11.70
4.6
3.3
0.0
0.0
estimate
0.00
44
105
47
165
3.46
11.17
4.8
2.7
—
—
—
0
0
60
275
2.73
8.77
3.5
2.7
0.7
0.9
e6/l
0.42
46
163
78
408
2.55
8.71
4.8
3.3
0.0
0.0
estimate
0.50
42
102
180
1462
5.39
7.68
17.8
12.4
74.8
76.3
ml/min/173m2
0.54
168
1193
15
30
5.34
7.31
3.7
2.6
18.5
16.2
%
—
10
16
100
646
2.16
6.31
4.7
3.7
—
—
—
0
0
182
1609
4.11
5.42
5.5
5.7
2.5
2.5
mmol/l
0.02
167
1472
183
1652
3.92
4.43
19.3
17.1
139.4
139.7
mmol/l
0.96
183
1608
126
962
1.92
4.29
4.1
4.7
7.0
6.9
mmol/l
0.07
117
911
183
1657
3.83
4.27
19.3
17.2
4.0
4.0
mmol/l
0.56
183
1616
178
1561
3.22
4.11
4.9
5.1
6.2
6.2
mmol/l
0.15
164
1406
174
1519
2.73
3.84
4.4
4.5
1.3
1.3
mmol/l
0.07
159
1382
10
27
3.85
3.40
1.4
2.4
105.1
104.9
mmol/l
—
10
27
171
1510
2.32
3.16
15.8
13.4
27.2
26.2
mg/l
0.12
152
1185
175
1566
2.49
3.03
5.0
5.0
1.3
1.3
mmol/l
0.03
160
1427
176
1581
2.54
2.98
5.1
5.0
4.3
4.3
mmol/l
0.00
161
1454
97
744
1.62
2.73
5.4
4.5
12.1
14.4
umol/l
1.41
92
708
169
1523
1.99
2.35
6.7
7.0
40.7
41.2
mmol/mol
0.38
158
1407
11
41
2.79
2.32
1.3
2.5
1.5
1.7
mg/l
0.65
11
36
10
37
2.80
2.14
3.2
2.2
146.2
129.6
g/l
—
10
25
99
797
1.51
2.06
6.9
6.3
4.4
4.5
e9/l
0.14
82
706
66
489
1.54
2.02
1.8
2.2
56.7
58.7
u/l
0.24
61
457
33
209
1.70
1.90
4.0
6.0
0.9
1.0
mmol/l
0.98
33
194
22
128
1.81
1.69
2.3
1.5
444.4
374.2
nmol/l
0.54
22
117
6
19
3.23
1.67
1.3
1.4
—
—
—
0
0
130
1133
1.47
1.65
3.8
3.9
9.9
11.3
mm/h
0.61
120
1033
5
14
3.64
1.62
2.0
1.4
30.1
16.3
ug/l
—
5
14
16
86
1.94
1.55
5.3
1.4
12.2
6.4
ug/l
0.35
11
65
147
1331
1.46
1.37
13.9
14.8
38.2
40.2
%
0.80
87
844
0
40
0.00
1.34
0.0
1.2
—
—
—
0
0
118
1034
1.37
1.29
3.1
2.9
15.0
15.1
pmol/l
0.06
103
912
5
18
2.82
1.29
1.4
1.6
—
—
—
0
0
6
25
2.44
1.25
1.7
1.6
—
—
—
0
0
26
174
1.57
1.23
4.0
3.3
5.9
5.8
kpa
0.18
26
168
86
722
1.35
1.22
4.7
6.5
1.2
1.2
mmol/l
0.24
61
630
13
221
0.56
1.22
6.7
7.4
12.6
11.6
kpa
0.38
13
216
13
221
0.56
1.22
6.8
7.4
5.3
5.1
kpa
0.40
13
215
83
702
1.32
1.10
4.3
3.8
40.0
50.7
ng/l
0.39
66
541
5
21
2.42
1.09
3.0
2.0
—
—
—
0
0
7
32
2.23
1.09
1.1
1.3
—
—
—
0
0
62
506
1.33
1.04
2.0
2.1
82.1
74.7
nmol/l
1.21
55
438
7
34
2.10
1.04
1.1
1.3
—
—
—
0
0
22
148
1.55
1.03
3.0
2.6
4.4
4.6
kpa
0.20
22
141
22
148
1.55
1.03
4.0
7.1
1.3
1.4
mmol/l
0.13
22
143
147
1357
1.37
1.01
3.8
3.8
2.0
2.1
mu/l
0.32
136
1214
81
693
1.29
0.96
1.5
2.0
86.9
92.4
pmol/l
0.55
41
404
18
118
1.58
0.95
1.1
1.2
—
—
—
0
0
24
170
1.47
0.91
3.8
2.4
497.4
255.2
u/l
1.03
24
157
40
314
1.35
0.86
1.3
1.6
2.0
1.2
mg/l
0.62
29
249
15
97
1.59
0.84
1.6
2.1
0.9
1.2
%
1.36
15
97
18
122
1.53
0.83
2.6
2.0
68.9
67.0
g/l
0.47
18
106
53
440
1.28
0.77
1.6
1.7
1.5
1.4
mmol/l
0.51
39
359
7
38
1.87
0.74
1.7
1.5
—
—
—
0
0
7
43
1.65
0.67
1.9
1.4
—
0.9
—
0
5
5
28
1.81
0.66
2.2
2.0
9.6
230.8
u/ml
—
5
18
65
563
1.23
0.66
2.1
2.6
208.1
204.6
ug/l
0.03
57
514
13
187
0.67
0.65
6.7
8.2
125.8
125.5
g/l
0.03
13
181
5
29
1.74
0.64
3.0
1.9
—
—
—
0
0
5
29
1.74
0.64
3.0
1.9
—
—
—
0
0
106
968
1.21
0.64
2.6
3.3
58.9
60.5
u/l
0.04
96
896
17
230
0.71
0.61
4.7
7.3
—
—
—
0
0
56
482
1.23
0.60
2.6
2.8
9219.4
10619.6
umol/l
0.05
48
424
6
37
1.64
0.56
1.0
1.1
—
—
—
0
0
12
82
1.49
0.56
1.8
1.8
46.1
45.3
nmol/l
0.05
12
77
14
192
0.71
0.55
1.3
1.3
1.1
17.2
u/ml
—
7
62
35
294
1.23
0.47
1.6
1.9
32.3
29.8
s
1.61
35
282
57
504
1.19
0.46
2.3
2.3
161.6
362.2
u/l
0.76
52
469
5
31
1.63
0.43
1.8
7.3
—
139.2
—
0
5
5
33
1.53
0.41
1.0
1.4
3.7
4.0
mmol/l
—
5
33
0
15
0.00
0.41
0.0
1.2
—
—
—
0
0
0
15
0.00
0.41
0.0
1.0
—
—
—
0
0
0
17
0.00
0.41
0.0
2.2
—
—
—
0
0
0
19
0.00
0.39
0.0
3.7
—
47.8
—
0
5
65
590
1.15
0.38
2.5
3.2
1417.2
1441.4
ng/l
0.01
58
512
6
43
1.41
0.35
1.0
1.0
—
—
—
0
0
16
127
1.28
0.35
1.9
2.2
71.4
63.1
ml/min/173m2
—
7
51
71
655
1.13
0.33
4.4
4.0
35.0
35.2
g/l
0.07
64
607
7
96
0.72
0.31
2.0
1.4
—
—
—
0
0
43
384
1.15
0.31
1.6
2.0
3.1
2.8
mg/l
0.38
35
324
8
106
0.74
0.30
1.6
1.8
—
—
—
0
0
7
56
1.26
0.30
1.0
1.4
—
—
—
0
0
14
114
1.25
0.26
1.9
2.0
40.6
34.5
u/l
—
9
95
5
38
1.32
0.23
1.0
1.4
2.2
3016.5
e6/l
—
5
33
7
91
0.76
0.23
1.6
2.0
—
—
—
0
0
5
42
1.20
0.21
3.8
3.9
14.6
24.1
mg/l
—
5
31
0
11
0.00
0.21
0.0
2.2
—
—
—
0
0
0
10
0.00
0.21
0.0
2.3
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
0
13
0.00
0.21
0.0
1.0
—
—
—
0
0
0
13
0.00
0.21
0.0
1.1
—
0.5
—
0
7
0
14
0.00
0.20
0.0
1.0
—
1.2
—
0
5
74
706
1.08
0.17
2.1
2.2
—
—
—
0
0
20
178
1.14
0.16
1.9
2.0
—
—
—
0
0
45
428
1.07
0.11
1.4
1.5
22.3
19.3
nmol/l
0.47
37
367
5
45
1.11
0.10
1.0
1.2
—
—
—
0
0
5
48
1.04
0.09
1.0
1.4
11.3
11.6
g/l
—
5
39
26
243
1.08
0.09
6.9
6.4
104.6
104.5
mmol/l
0.03
26
235
10
88
1.14
0.08
5.9
3.8
23.7
24.2
mmol/l
—
10
80
10
90
1.12
0.05
6.9
10.2
24.7
24.8
mmol/l
—
10
81
11
100
1.11
0.05
1.2
1.4
—
—
—
0
0
26
253
1.03
0.01
2.1
1.9
—
—
—
0
0
34
346
0.98
0.00
2.6
2.2
—
—
—
0
0
34
339
1.00
0.00
2.2
1.8
1618.7
1153.8
nmol/l
1.84
26
269
39
392
0.99
0.00
1.7
1.9
450.3
17485048.1
pmol/l
0.50
31
326
25
248
1.01
0.00
1.4
1.2
10.7
1.4
u/ml
0.48
11
70
18
182
0.99
0.00
2.0
1.9
—
—
—
0
0
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
0.00
0.0
4.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
9
0.00
0.00
0.0
2.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
2.0
—
—
—
0
0
0
6
0.00
0.00
0.0
4.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
0
6
0.00
0.00
0.0
1.8
—
—
—
0
0
0
9
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
210.5
—
0
6
0
9
0.00
0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
0.00
0.0
2.1
—
13.6
—
0
7
5
52
0.96
0.00
1.0
1.3
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
2.0
—
0.3
—
0
7
0
9
0.00
0.00
0.0
1.0
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint CD2_INSITU_PROSTATE_EXALLC and mortality.
Females
No dataMales
No dataMortality risk
Mortality risk for people of age
years, who have CD2_INSITU_PROSTATE_EXALLC.| N-year risk | Females | Males |
|---|---|---|
| 1 | No data | No data |
| 5 | No data | No data |
| 10 | No data | No data |
| 15 | No data | No data |
| 20 | No data | No data |
Relationships between endpoints
↥Index endpoint: CD2_INSITU_PROSTATE_EXALLC – Carcinoma in situ of prostate
GWS hits: 2
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data